首页> 外文期刊>Japanese journal of clinical oncology. >Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer: Japan Clinical Oncology Group study (JCOG1601, RESPOND)
【24h】

Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer: Japan Clinical Oncology Group study (JCOG1601, RESPOND)

机译:随机阶段III研究评估遗传术治疗I / II舌癌的预防性颈部解剖的价值:日本临床肿瘤学群体研究(JCOG1601,回应)

获取原文
获取原文并翻译 | 示例
           

摘要

For stage I/II tongue cancer patients, it is controversial whether prophylactic neck dissection should be performed with partial glossectomy. Based on the evidence of the primary tumor's depth of invasion as a predictive factor of occult lymph node metastases and a prognostic factor of disease-free survival, randomized phase III trial was initiated in November 2017 to evaluate the omission value for prophylactic neck dissection for stage I/II tongue cancer with 3-10 mm of depth of invasion. In 5 years, 440 patients will be accrued from 28 institutions. The primary end point of the study is the overall survival, whereas the secondary end points are relapse-free survival, local relapse-free survival, proportion of unresectable relapse and of cervical lymph node relapse, postoperative function (paralysis of the accessory and facial nerves and subjective symptoms) and adverse events. This trial has been registered with the UMIN Clinical Trials Registry (registration number: UMIN000030098; http://www.umin.ac.jp/ctr/index.htm).
机译:对于阶段I / II舌癌患者,它是有争议的是否应通过部分光泽剖面进行预防性颈部解剖。基于原发性肿瘤的侵袭症的证据,作为隐匿性淋巴结转移的预测因素和无病生存期的预后因素,2017年11月启动了随机期III试验,以评估预防颈部解剖阶段的遗漏值I / II舌癌,患有3-10毫米的入侵。在5年内,440名患者将从28个机构累积。研究的主要终点是整体存活率,而次要终点是无复发存活,局部复发存活,不可切开的复发比例和颈淋巴结复发,术后功能(垂直和面神经瘫痪和主观症状)和不良事件。该试验已在UMIN临床试验登记处注册(注册号:UMIN000030098; http://www.umin.ac.jp/ctr/index.htm)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号